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Antibody protectionon complex (EFC) is comprised of at least eight transmembrane proteins that are
conserved in all poxviruses. However, neither the physical structure of the EFC nor the immunogenicity of
the individual components has been determined. We prepared soluble forms of two EFC components, A28
and H2, by replacing the transmembrane domain with a signal peptide and adding a polyhistidine tail. The
proteins were expressed by baculoviruses, secreted from insect cells, puriﬁed by afﬁnity chromatography and
used to raise antibodies in rabbits. The antibodies recognized the viral proteins but only the antibody to
recombinant A28 bound intact virions and neutralized infectivity. Analyses with a set of overlapping peptides
revealed a neutralizing epitope between residues 73 and 92 of A28. Passive immunization of mice with IgG
puriﬁed from the anti-A28 serum provided partial protection against a vaccinia virus intranasal challenge,
whereas IgG from the anti-H2 serum did not.
Published by Elsevier Inc.Introduction
Smallpox was eradicated three decades ago, after which vaccina-
tion largely ceased (Fenner et al., 1988), leaving a large segment of
the present population without protective immunity. Because of
concerns regarding the use of variola virus as a biological weapon,
there has been renewed interest in smallpox vaccines. The licensed
smallpox vaccines, which consist of live vaccinia virus (VACV), are
highly efﬁcacious but can have serious side effects particularly in
individuals who are immunocompromised or have a history of
eczema (Fulginiti et al., 2003). A second-generation vaccine,
produced by modern tissue culture methods, has recently been
licensed in the United States but is likely to have a safety proﬁle
similar to previous vaccines (Monath et al., 2004). Highly attenuated
strains of VACV are being clinically tested (Kenner et al., 2006;
Parrino et al., 2007; Vollmar et al., 2006) but their efﬁcacy and safety
remain to be established. Efforts are also being made to develop live
VACV vaccines with speciﬁc attenuating deletions (Coulibaly et al.,
2005; Tartaglia et al., 1992; Vijaysri et al., 2008) and recombinant
DNA and protein vaccines that target speciﬁc poxvirus components
(referenced below). However, these approaches are at an early stage
and their development requires in depth knowledge of poxvirus
structure, replication and host interactions.derabad 500032, India.
nc.There are two major infectious forms of VACV and related
orthopoxviruses (Condit et al., 2006; Moss, 2007; Smith et al.,
2002). The mature virion (MV), which contains a DNA-protein core
surrounded by a lipoproteinmembrane, can be released by cell lysis. In
addition, a subset of MVs are wrapped in additional membranes,
transported to the periphery of the cell and released as the enveloped
virion (EV). The EV is essentially an MV with an outer membrane,
although there are some differences. For infection of new cells, the EV
membrane is disrupted and the MV membrane fuses with the plasma
or endosomal membrane to transfer the core into the cytoplasm (Law
et al., 2006; Moss, 2006; Townsley et al., 2006). Antibodies to MV and
EV membrane proteins are induced by live virus infection and the
combination contributes to the protection against an orthopoxvirus
challenge (Appleyard et al., 1971; Boulter et al., 1971; Law et al., 2005;
Turner and Squires, 1971).
Approximately 20 proteins are associated with the MV
membrane and six with the EV membrane (Condit et al., 2006).
Certain MV and EV membrane proteins have been reported to
serve as targets for protective antibodies in mice. Such MV proteins
include: L1 (Fogg et al., 2004), H3 (Davies et al., 2005), A27
(Demkowicz et al., 1992; Lai et al., 1991) and D8 (Sakhatskyy et al.,
2006); the EV proteins that produce protective antibodies include A33
(Fang et al., 2006; Fogg et al., 2004; Galmiche et al., 1999) and B5 (Fogg
et al., 2004; Galmiche et al., 1999). Multicomponent vaccines,
consisting ofMV and EV proteins or DNAencodingMV and EV proteins,
provide greater protection than single component vaccines (Fogg et al.,
2004, 2007; Hooper et al., 2003, 2004; Sakhatskyy et al., 2006).
However, even the multicomponent protein and DNA vaccines are
inferior to live VACV and none of the testedMV proteins appear to be a
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whohave received the licensed smallpox vaccine (Benhnia et al., 2008).
For these reasons, it may be useful to identify additional viral protein
targets.
Recently, eightMV transmembraneproteins referred to as the entry/
fusion complex (EFC) were shown to mediate or regulate VACV entry
andmembrane fusion (Izmailyan et al., 2006; Ojeda et al., 2006a; Ojeda
et al., 2006b; Senkevich and Moss, 2005; Senkevich et al., 2005;
Senkevich et al., 2004b; Townsley et al., 2005a; Townsley et al., 2005b).
Depending on the physical structure of the EFC and the topology in the
viral membrane, some of the individual protein components might
serve as additional targets of protective antibodies. For the present
study, we expressed soluble recombinant forms of A28 (rA28) and H2
(rH2), the ﬁrst two identiﬁed components of the EFC, in insect cells.
Both proteins induced antibodies to the viral proteins in rabbits, but
only rA28 elicited neutralizing antibodies and passively protectedmice
against an intranasal (IN) challenge. A neutralizing epitope on A28was
mapped to a 20 amino acid peptide.Fig. 1. rA28 and rH2 proteins. (A) Natural A28 and H2 and rA28 and rH2 are depicted
with amino acid numbers. Transmembrane domains are represented as grey rectangles
and the melittin signal sequence as awhite rectangle. Lollipops indicateN-glycosylation
consensus sequences and arrowheads are sites of signal sequence cleavage. H6
represents the 6-histidine tail. (B) The recombinant proteins were secreted into the
medium and puriﬁed by nickel-NTA afﬁnity chromatography, separated by SDS-PAGE
under reducing conditions and stained with Coomassie blue. The numbers on the left
correspond to the electrophoretic positions and masses in kDa of marker proteins. (C)
rA28was left untreated (lane 1) or was treatedwith PNGase F (lane 2) or EndoH (lane 3),
separated by SDS-PAGE under reducing conditions and transferred to a nitrocellulose
membrane. The blot was probed with a monoclonal antibody directed against the
histidine tag.
Fig. 2. Characterization of anti-A28 antibodies. (A) Proteins from VACV infected (+) or
uninfected (−) cell lysates were separated by SDS-PAGE under reducing conditions and
probed with anti-sera from two rabbits (NEL-1 and NEL-2) that were immunized with
rA28. The positions of marker proteins are shown according to kDa. NEL-2 antibody
apparently cross-reacts with a protein of about 50-kDa. (B) Increasing concentrations of
puriﬁed IgG from NEL-1 were incubated with ELISA plates coated with untreated or
PNGase F treated rA28. (C) ELISA assays were performed using plates coated with
puriﬁed VACV WR MV particles. Bound IgG was detected using peroxidase-conjugated
anti-rabbit secondary antibody followed by 3,3,5,5-tetramethylbenzidine substrate.
Fig. 3. Characterization of anti-H2 antibodies. (A) Cells were infected with vH2i
(Senkevich and Moss, 2005) in the absence (−) or presence (+) of 100 μM IPTG and the
proteins from lysates were separated by SDS-PAGE under reducing conditions. Western
blots were probed with anti-sera from two rabbits (03 and 04) immunized with rH2.
The positions of marker proteins are shown according to kDa. (B) Increasing
concentrations of puriﬁed IgG from pre-immune and immune sera from rabbits 03
and 04 were incubated with ELISA plates coated with rH2. (C) ELISA assays were
performed using plates coated with puriﬁed VACV WR MV particles. Bound IgG was
detected using peroxidase-conjugated anti-rabbit secondary antibody followed by
3,3,5,5-tetramethylbenzidine substrate.
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Expression of secreted rA28 and rH2
The A28L (VACWR151) and H2R (VACWR100) open reading
frames (ORFs) encode proteins of 16.3 and 21.5 kDa, respectively.
Each protein has an N-terminal transmembrane domain that is
anchored in the MV membrane. For solubility and ease of
puriﬁcation, recombinant A28L and H2R genes were constructed
by replacing DNA encoding the N-terminal segments including the
transmembrane domains with sequences encoding the honeybee
melittin signal peptide and adding sequences encoding 6 histidines
to the C-termini (Fig. 1A). The modiﬁed genes were individually
cloned in baculovirus vectors and expressed in insect cells. The
recombinant proteins were secreted into the medium, puriﬁed on
Ni-NTA agarose, and analyzed by sodium dodecyl sulfate-polyacry-
lamide gel electrophoresis (SDS-PAGE). The puriﬁed rA28 was
resolved as a doublet that migrated more slowly than predicted
for a mass of 14.8 kDa, calculated for the product after signal
peptide cleavage (Fig. 1B). In contrast, rH2 migrated as a single band
close to the expected 20-kDa mass (Fig. 1B). rA28 contains three
potential N-glycosylation sites (Fig. 1A) and following denaturation
and treatment with peptide:N-glycosidase F, a single more rapidly
migrating band was resolved (Fig. 1C). Partial deglycosylation was
achieved with endoglycosidase H (Fig. 1C). Glycosylation of rA28Fig. 4. Neutralization of VACV by A28 antibodies. (A) Increasing concentrations of
puriﬁed IgG from rabbit NEL-1 or NEL-2 immunized with rA28 or from unimmunized
NEL-1 rabbit were incubated with puriﬁed VACV WR-GFP before adsorption to cells. In
addition, NEL-1 anti-A28 IgG was added after binding virus to cells. Infected cells
expressing GFP were determined by ﬂow cytometry. (B) Similar to panel A except that
IgG was from rabbit 03 prior to or after immunization with recombinant rH2.
Fig. 6. A28 peptide ELISAs. (A) Fifteen biotinylated 20 amino acid peptides that
overlapped by 11 residues and scanned the entire A28 protein were synthesized. The
peptides were: A1 (1–20), B1 (10–29), C1 (19–38), D1 (28–47), E1 (37–56), F1 (46–65),
G1 (55–74), H1 (64–83), A2 (73–92), B2 (82–101), C2 (91–110), D2 (100–119), E2 (109–
128), F2 (118–137) and G2 (127–146). (B) Each peptidewas used to coat wells of an ELISA
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A28 is not glycosylated during a normal VACV infection because the
ectodomain is in the cytoplasm rather than the endoplasmic
reticulum (Senkevich et al., 2004a). H2 has no predicted N-
glycosylation sites, so in this respect the recombinant and natural
proteins were identical.
Anti-A28 polyclonal antibodies bind and neutralize VACV
Rabbits immunized with the puriﬁed recombinant proteins
generated antibodies that bound authentic A28 and H2. The reactivity
of the anti-A28 anti-sera was determined by probing lysates from
uninfected and VACV-infected cells on Western blots. A prominent
band corresponding to A28 was seen only in infected cells (Fig. 2A).
Puriﬁed IgG reacted similarly with both the glycosylated and
deglycosylated recombinant proteins in an ELISA format (Fig. 2B).
Furthermore, the anti-A28 IgG was able to bind to ELISA plates coated
with puriﬁed VACV virions (Fig. 2C), indicating that the antibody
recognized an epitope exposed on the surface of MVs.
Anti-sera from the rabbits immunizedwith rH2 reacted speciﬁcally
with cell lysates from cells that were infected with a recombinant
VACV that inducibly expressed authentic H2. In addition to the
expected 21.5 kDa band, material migrating at about 90-kDa reacted
with the antibody (Fig. 3A). Neither bandwas detected in lysates of the
H2 inducible virus in the absence of IPTG (Fig. 3A), suggesting that the
higher mass band may be an aggregate of H2 or a complex of H2 with
other proteins. The puriﬁed IgG reacted with rH2 as determined by
ELISA (Fig. 3B). However, there was low reactivity with puriﬁed VACV
virions compared to the anti-A28 antibody (Fig. 3C), suggesting the
absence of a readily accessible H2 epitope on the intact virion.
The ability of anti-A28 antibody to neutralize VACV infectivity was
tested using a ﬂow cytometry assay that is dependent on expression of
enhanced green ﬂuorescent protein (Earl et al., 2003). IC50 values of
3.7 and 22 μg/ml were obtained for total IgG from sera of the two
rabbits (Fig. 4A). These numbers can be compared to the IC50 values of
2.3 and 6.7 μg/ml for rabbit polyclonal IgG to L1 and VIG, respectively,
using the same neutralization assay (Lustig et al., 2005). Similar
neutralizing activity was obtained when the antibody to A28 was
added following adsorption of virus to cells (Fig. 4A), suggesting that
inhibition occurred at a post-attachment step. The anti-H2 IgG had no
neutralizing activity (Fig. 4B), consistent with the low ability to bind
virions (Fig. 3C).Fig. 5. rA28 blocked virus neutralization. IgG puriﬁed from either anti-A28 or pre-
immune serumwas incubated with rA28, rH2 or no protein (−) and then incubated with
VACV WR-GFP. Neutralization was determined as in Fig. 4.
plate, which was incubated with dilutions of anti-A28 serum. Endpoints were
determined as the serum dilution resulting in an absorbance greater than 2 standard
deviations above the absorbance in wells not incubated with serum.Antibody binding to residues 73–92 of A28 neutralize VACV
rA28 blocked the VACV neutralizing activity of the anti-A28 IgG,
conﬁrming the speciﬁcity of the antibody (Fig. 5). As a control, rH2,
which was also expressed in insect cells and puriﬁed by Ni-NTA
chromatography, had no blocking activity when added to the anti-A28
IgG (Fig. 5).
A peptide scan was performed to locate binding and neutralizing
epitopes on A28. Biotinylated 20 amino acids long peptides, which
overlapped by 11 amino acids, were bound to streptavidin-coated
plates (Fig. 6A). The plate was incubated with anti-A28 IgG and
binding was determined by ELISA. Positive signals were detected
throughout the length of A28, but the strongest binding peptides were
located in the C-terminal one-third. Poor solubility, however, may
have contributed to low reactivity of some peptides.
Each of the individual peptides bound to streptavidin conjugated
beads were used to afﬁnity purify IgG, which was then eluted and
tested for neutralizing activity. Antibody eluted from the A2 peptide
(residues 73 to 92) was the only one that had a lower EC50 (0.11 μg/ml)
than the total anti-A28 IgG (Fig. 7). Antibody eluted from the other
Fig. 8. A28 antibodies protected mice from a VACV IN challenge. (A) Groups of ten 6-
week-old female BALB/c mice received 5 mg of rabbit anti-A28 IgG from NEL-1, 5 mg of
VIG, PBS, or nothing by the intraperitoneal route. After 24 h, all mice except the
untreated groupwere challenged INwith 1×104 PFU of VACVWR and weighed daily for
14 days. Percentages of initial mean weights of all mice and standard errors of the
means are shown. (B) Protocol as in the above panel except that pre-immune and anti-
H2 IgG was from rabbit 03. † represents a mouse sacriﬁced because its weight dropped
below 70%.
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IgG, suggesting non-speciﬁc binding to the beads.
Anti-A28 antibody protected mice from an intranasal (IN) VACV
challenge
A mouse IN infection model employing the WR strain of VACV
(Turner,1967;Williamson et al., 1990) was used tomeasure protection
afforded by passively administered anti-A28 IgG. Weight loss
correlates with virus replication in the lungs and provides a non-
invasive way of measuring disease in individual animals during onset
and recovery phases (Law et al., 2005). Groups of 10 mice received
anti-A28 IgG, anti-H2 IgG, human vaccinia immune globulin (VIG) or
phosphate-buffered saline (PBS) by the intraperitoneal route andwere
challenged 1 day later with 1×104 plaque forming units (PFU) (∼0.7
LD50) of VACV WR by the IN route. In addition, a group of untreated
mice served as aweight control. All of the challenged mice lost weight
(Fig. 8A). However, mice immunized with anti-A28 antibody lost
signiﬁcantly less weight than the control mice (p=0.0079 for days 7–
11), and none had to be sacriﬁced (Fig. 8A). The protectionwas similar
to that provided by VIG (Fig. 8A).
Since non-neutralizing antibody can sometimes protect in vivo,
mice were also passively immunized with anti-H2 IgG. However,
weight loss was similar to that of mice that received the pre-immune
IgG (Fig. 8B).
Discussion
More than 20 proteins are associated with the MV membrane but
little is known about their organization. Four of these proteins, namely
A27 (Demkowicz et al., 1992; Lai et al., 1991), D8 (Sakhatskyy et al.,
2006), H3 (Davies et al., 2005) and L1 (Fogg et al., 2004) induce
neutralizing antibody and provide some protection after active protein
or passive antibody immunization. The purpose of the present study
was to provide an initial examination of the immunogenicity of VACV
EFC component proteins and determine their ability to induce
neutralizing and protective antibodies. A28 and H2 were chosen
because they were the ﬁrst two of the eight EFC proteins discovered
(Senkevich and Moss, 2005; Senkevich et al., 2004b). A baculovirus
expression system was used and in each case the N-terminal
transmembrane domain was replaced with a signal peptide so that
the proteins would be secreted into the medium of insect cells. In
general, the secretory system provides correct folding and simpliﬁes
further puriﬁcation of a soluble protein. Although A28 is notFig. 7. Neutralizing activities of antibodies that bound to speciﬁc peptides. Anti-A28 IgG
was incubated with biotinylated A2 peptide that had been bound to streptavidin beads.
Bound IgG was eluted and used in a neutralization assay as described in Fig. 4. IgG
afﬁnity puriﬁed using biotinylated full-length A28 was analyzed for comparison.glycosylated during a normal virus infection because the C-terminus
is cytoplasmic (Senkevich et al., 2004a), there are three cryptic N-
glycosylation sites that were utilized in the insect cell secretion
system. Complete enzymatic removal of the carbohydrate, however,
required denaturation so the decisionwasmade to immunizewith the
glycosylated product. In the future, it would be interesting to remove
the glycosylation motifs by mutagenesis, although this would also
alter the natural protein. Since H2 had no glycosylation motifs, this
was not an issue.
rA28 and rH2 induced antibodies in rabbits that recognized the
authentic viral proteins on Western blots, but only the anti-A28
antibody bound to puriﬁed MVs, indicating the presence of an
available epitope on the membrane surface. The failure of the anti-
H2 antibody to react with MVs could be due to the absence of exposed
epitopes on the virion surface or to some differences between the
recombinant and virion-associated proteins. Recent data indicate that
A28 and H2 interact with each other (Nelson et al., 2008), suggesting
the possibility that much of H2 may be buried. In view of the low
binding of H2 antibody to virions, it was not surprising that it did not
neutralize infectivity. In contrast, the A28 antibody neutralized
infectivity whether it was allowed to interact with the virus before
or after adsorption to cells. The latter ability was consistent with the
role of the EFC in entry rather than attachment.
A peptide scan of the A28 protein was carried out to determine
binding epitopes. Although there was binding throughout the length
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However, low or no binding may be related to poor solubility of some
peptides. To determine neutralizing epitopes, the biotinylated pep-
tides were bound to streptavidin beads and incubated with IgG. The
IgG was then eluted and tested for neutralization of VACV. The most
potent neutralizing activity was obtained with the antibodies that
bound to the peptide containing residues 73 to 92. The IC50 of the
latter was lower than that of the total IgG. IgG eluted from the other
peptides had IC50 values that were similar or higher than the total. It
will be interesting to see whether this peptide is also a good
immunogen. Additional conformational epitopes that were not
detected in the peptide scan may also be present on A28.
The protective abilities of the A28 and H2 antibodies were tested in
mice by administering the IgG intraperitoneally and challenging with
the VACV WR strain by the IN route. The challenge dose (∼0.7 LD50)
caused a fairly uniformweight loss, after which most mice recovered.
The H2 antibody had no discernible protective effect, whereas the A28
antibody was about as effective as VIG in partially preventing weight
loss. Protection against more stringent challenges would likely require
a combinationwith antibody to an EV protein, as previously shown for
L1 MV protein (Lustig et al., 2005). In conclusion, we have
demonstrated that at least one EFC protein is a target of neutralizing
and protective antibodies.
Materials and methods
Construction of recombinant baculoviruses
Overlapping polymerase chain reaction was used to replace DNA
encoding the N-terminal transmembrane domain of A28 with
sequences encoding the honeybee melittin signal sequence and
append DNA encoding six histidines to the C-terminus. The resulting
product was then TOPO cloned into pBlueBac4.5/V5-His (Invitrogen,
Carlsbad, CA). Using the Bac-N-Blue Transfection Kit (Invitrogen), the
plasmid was then recombined with baculovirus Bac-N-Blue DNA in
Sf9 cells and virus plaques were picked and puriﬁed. Genomic DNA
was isolated using the DNA Blood Mini Kit (Qiagen, Germantown,
MD), PCR ampliﬁed and partially sequenced to verify the construct. A
similar procedure was used to construct a rH2 open reading frame
with the melittin signal sequence and a six-histidine tag using the
pMelBac B Baculovirus Transfer Vector (Invitrogen) and recombine the
DNA into baculovirus. Recombinant baculoviruses were propagated
using Sf9 cells grown in either TNM-FH or Sf-900 II SFM medium for
rA28 and rH2, respectively. Virus titers were determined as described
in the BaculoDirect Baculovirus Expression System-User Manual.
Expression and puriﬁcation of recombinant proteins
Approximately 6 L of High Five cells (Invitrogen) were infected at a
multiplicity of 0.1 PFU per cell and incubated for 96 or 30 h for
production of rA28 and rH2, respectively. The medium was collected,
clariﬁed by centrifugation, and concentrated on a Labscale TFF System
(Millipore, Billerica, MA), with three 50 cm2 Millipore PLCCC5
concentration cartridges. Samples were collected and clariﬁed and
200 ml of the concentrated protein was incubated with 30 ml of Ni-
NTA agarose (Qiagen) on a rotary shaker overnight at 4 °C. The beads
were washed and the bound proteins eluted with increasing
concentrations of imidazole. The eluted proteins were dialyzed
against 10% glycerol in PBS. The protein dialysate was collected and
the concentration determined using the Bradford Coomassie Protein
Assay (Pierce, Rockford, IL).
Deglycosylation of rA28
rA28 (280 ng) was denatured in 0.5% SDS and 1% β-mercaptoetha-
nol for 10 min at 100 °C. The denatured protein was then added to therespective buffer: 50 mM sodium citrate, pH 5.5 for Endo H and
50 mM sodium phosphate, pH 7.5 with 1% NP-40 for PNGase F (New
England Biolabs, Ipswich, MA). The protein was incubated for 1 h at
37 °C with 1000 U of enzyme. The protein was then diluted with 2×
SDS gel loading buffer (Quality Biological, Derwood, MD), resolved by
SDS-PAGE, transferred to a nitrocellulose membrane, stained with
anti-Tetra-HIS mouse monoclonal antibody (Qiagen) followed by
peroxidase-conjugated anti-mouse goat antibody (Pierce) and
detected with a chemiluminescence detection kit (Pierce).
Western blot of A28 and H2 proteins
BS-C-1 cells in a 6-well plate were infected with 5 PFU/cell of VACV
WR or vH2i in the presence or absence of 100 μM IPTG. After 24 h, the
cells were lysed in 2×SDS gel loading buffer (Quality Biological),
resolved by SDS-PAGE, transferred to a nitrocellulose membrane,
analyzed with 1:1000 dilution of anti-A28 or-H2 serum followed by
peroxidase-conjugated anti-rabbit goat antibody (Pierce) and
detected with a chemiluminescence detection kit (Pierce).
Antibody induction and puriﬁcation
Two rabbits were immunized with 100 μg of the rA28 or rH2
protein in Freund's Complete Adjuvant and three subsequent times
with 100 μg of the recombinant protein in Freund's Incomplete
Adjuvant at Spring Valley Laboratories (Woodbine, MD). The poly-
clonal rabbit anti-serum was incubated with protein A agarose,
washed, and eluted with IgG elution buffer (pH 2.8) from Pierce. The
eluted IgG was immediately neutralized with Tris and then dialyzed
into PBS. To afﬁnity purify antibody speciﬁc to regions of A28,
biotinylated peptides synthesized by Mimotopes (Clayton, Victoria,
Australia) as 20mers with 11 amino acid overlap were resuspended in
50% acetonitrile, diluted in Tris-buffered saline and incubated with
immobilized streptavidin (Pierce) for 30min at 4 °C, blocked, and then
washed with Tris-buffered saline. The peptide bound streptavidin
beads were then incubated with puriﬁed polyclonal anti-A28 IgG
overnight at 4 °C, washed, and the bound IgG was eluted with IgG
elution buffer (pH 2.8) and immediately neutralized with Tris.
Concentrations were calculated by measuring the A280 nm and
dividing by the IgG extinction coefﬁcient of 1.35.
ELISA
Polystyrene plates with 96-well round bottoms (Corning, Inc.,
Acton, MA) were coated by overnight incubation with either 60 ng/
well of recombinant protein at 4 °C or 1x106 PFU/well of puriﬁed VACV
WR at 37 °C. Virus coated plates were inactivated with 2%
paraformaldehyde for 10 min at 4 °C. For peptide ELISAs, streptavidin
plates (Pierce) were coated with 1:1000 dilutions of peptides in PBS
for 1 h. The plates were then washed in a solution of 27 g of NaCl and
3 ml of Tween 20 in 3 L of deionized water. Plates were incubated for
1 h at 37 °C with blocking buffer (5% nonfat dry milk in PBS with 0.2%
Tween 20) and washed. Mouse or rabbit sera or puriﬁed IgG was
serially diluted in blocking buffer; 0.1 ml was added to each well, and
the plates were incubated for 1 h at 37 °C and thenwashed. Anti-rabbit
(Pierce) or anti-mouse (Roche Diagnostics, Indianopolis, IN) IgG
peroxidase-conjugated antibody, diluted 1:5000 in blocking buffer,
was added, and the plates were incubated for 1 h at 37 °C and then
washed. A ready-to-use solution of soluble 3,3,5,5-tetramethylbenzi-
dine (BM Blue, POD substrate; Roche Diagnostics) was added to the
plates, which were incubated at room temperature for 30 min. The
A370 and A492 were measured with a Spectra MAX Plus plate reader
(Molecular Devices, Sunnyvale, CA), and the endpoint titer was
calculated as the serum dilution resulting in an absorbance greater
than 2 standard deviations above the absorbance in wells not
incubated with antibody or serum.
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MV neutralization titers were determined by incubating IgG
dilutions in Eagle spinner medium with 2% heat inactivated fetal
bovine serum with the recombinant VACV vv-WR-NP-siinfekl-EGFP
(Anton et al., 1999; Norbury et al., 2002) (referred to here as WR-GFP),
and then determining the percentage of infected cells by ﬂow
cytometry (Earl et al., 2003). To test for cell post-attachment
neutralization, WR-GFP was ﬁrst incubated with cells for 1 h at 4 °C
and unbound virus was removed by washing with PBS. The cells were
then incubated with dilutions of IgG at 37 °C for 18 h and the
percentage of infected cells was determined by ﬂow cytometry. To
block neutralization, 7.5 μg/ml of recombinant protein was incubated
with 100 μg/ml of anti-A28 NEL-1 IgG for 1 h. The protein-antibody
mix was then incubated with WR-GFP and used to infect cells.
Infectivity measured as described above.
Passive immunization
Female 6-week-oldBALB/cmice (Taconic, Hudson,NY)were injected
intraperitoneally with 5 mg of puriﬁed IgG in two 1ml doses diluted in
PBS. Unimmunized mice were injected with the same volume of PBS.
The day after immunization, blood was collected from the tail vein, and
serumwas isolated fromclottedblood samples bycentrifugation. Serum
from each mouse was tested for A28 antibodies using rA28 ELISAs. One
day after immunization, mice were anesthetized by inhalation of
isoﬂurane and inoculated IN with a 20 μl suspension of 1×104 PFU of
puriﬁed VACVWR. They wereweighed daily for 2 weeks, and sacriﬁced
if they lost 30% of their initial body weight.
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